Clozapine monitoring: can long-term customers safely check much less usually?

Clozapine, an atypical antipsychotic, stays the only real treatment with demonstrated efficacy in decreasing each signs and relapse threat in adults with therapy resistant schizophrenia (NICE, 2015). Its use includes strict necessary blood monitoring because of the threat of agranulocytosis, an acute drop in circulating granulocytes that leaves the individual with very restricted capacity to struggle infections. Within the UK, sufferers are required to register with a clozapine monitoring service and full blood counts have to be monitored at the least weekly for the primary 18 weeks, at the least fortnightly between weeks 18 to 52, and at the least 4 weekly after one 12 months of therapy with secure full blood rely.

In the USA, the Meals and Drug Administration eliminated its necessary Threat Analysis and Mitigation Technique programme for clozapine in 2025, though blood monitoring remains to be really helpful. Within the UK, blood monitoring guidelines stay in place, however the Medicines and Healthcare merchandise Regulatory Company launched a assessment of its necessities in 2025. Curiosity in much less frequent testing grew throughout the COVID-19 pandemic, when some NHS trusts briefly moved low-risk sufferers to 12-weekly blood exams to cut back an infection threat. A small London examine of this variation discovered no circumstances of agranulocytosis over one 12 months (Oloyede et al., 2023).

This massive scale observational examine aimed to judge the security of 12-weekly monitoring of neutrophil rely in sufferers taking long-term clozapine (Taylor et al, 2025). Neutrophils are essentially the most plentiful sort of white blood cell, and they’re the immune system’s first responders to an infection.

Cells under a microscope — Neutrophils are essentially the most plentiful sort of white blood cell and are the immune system’s first responders to an infection.

Strategies

This was a retrospective, observational examine which included all registered sufferers on the Zaponex Therapy Entry System permitted for 12-weekly monitoring, registered March 2020 to November 2022, {followed} as much as August 2024. All had a paranoid schizophrenia prognosis. The sufferers and examine was primarily based within the UK.

The authors gathered knowledge through a clozapine monitoring service with out entry to affected person identifiers and due to this fact didn’t require affected person consent. Because the diminished monitoring was exterior the phrases of the product license, off-license kinds had been accomplished. It was not clear if it was the authors or accountable marketing consultant that accomplished these kinds.

The examine complied with the moral requirements of the UK Well being Analysis Authority. Strengthening the Reporting of Observational research in Epidemiology reporting tips had been additionally adhered to. The agreed standards included sufferers with no historical past of neutropenia and good compliance with clozapine therapy for at the least a 12 months. Sufferers with benign ethnic neutropenia (BEN: a congenital type of low neutrophil counts and most prevalent in individuals of African, Center Jap and West Indian ancestry) had been included.

Outcomes of curiosity included dying from clozapine induced agranulocytosis and improvement of hostile blood outcomes throughout follow-up. Sufferers had been followed-up till discontinuation of clozapine, loss to follow-up because of dying, or till the top of the examine interval in 2024.

A rear view mirror — This retrospective observational examine regarded again at UK affected person knowledge from 2020 to 2024.

Outcomes

A complete of 1,025 clozapine sufferers with a paranoid schizophrenia prognosis had been monitored at 12-weekly intervals. There was a wide range of ethnicities together with White, Black, Asian and combined. Total there have been extra males (69%) than females (31%) on this cohort examine with a imply age of 47 years outdated. The median follow-up time per participant was 4 years.

9 sufferers had a pink end result, this implies their white cell rely was lower than 3.0 x10⁹/L and/or their neutrophil counts was lower than 1.5 x10⁹/L.
34 sufferers had an amber end result which implies their white cell rely was between 3.0 x10⁹/L to three.5 x10⁹/L and/or their neutrophil counts was between 1.5 x10⁹/L to 2.0 x10⁹/L.

A pink result’s extra critical than an amber end result. Blood parameters for inexperienced, amber, pink outcomes for BEN sufferers are totally different in comparison with customary sufferers because of their chronically decrease neutrophil counts. BEN sufferers’ blood parameters are decided by marketing consultant haematologists. There have been no circumstances of agranulocytosis recorded. As a consequence of this, 83% sufferers continued on diminished frequency blood monitoring for the remainder of the examine, 2% stopped and 15% briefly interrupted diminished monitoring however restarted earlier than the top of the follow-up interval.

Eleven sufferers (1%) had been misplaced to follow-up. Through the examine, 42 sufferers (4%) died. Respiratory illness was by far the commonest reason for dying (22 deaths), {followed} by heart problems (9). The trigger was unknown for one more 9 deaths. Different causes had been substance misuse (3), most cancers (3), diabetes (2), seizure (1) and bowel obstruction (1), and one dying was recorded as clozapine associated. Some deaths had a couple of trigger recorded. Not one of the individuals who died had a pink or amber end result throughout 12-weekly monitoring, and no deaths had been brought on by agranulocytosis.

In abstract, there have been no circumstances of agranulocytosis and no deaths from agranulocytosis amongst long-term sufferers who moved to 12-weekly monitoring. Most sufferers (83%) stayed on 12-weekly monitoring for the remainder of the examine.

On this examine, the authors discovered an elevated variety of deaths from respiratory illness and used earlier research to notice that pneumonia might happen in those that begin clozapine therapy and suggested to place measures in place to cut back the chance of pneumonia such because the pneumococcal vaccine.

A reception desk in a hospital or clinical setting — It was secure for sufferers on this examine to cut back clozapine monitoring to 12-weekly.

Conclusions

The authors concluded that it was secure to cut back the frequency of clozapine monitoring to 12-weekly in long-term clozapine sufferers. Nonetheless, you will need to take into account the strengths and limitations of the examine earlier than drawing agency conclusions about wholesale modifications to monitoring.

Strengths and limitations

This examine has a number of strengths. The analysis query was clear, and the outcomes (agranulocytosis, deaths from agranulocytosis and irregular blood outcomes) had been the suitable ones for judging security. Everybody within the pattern had the identical prognosis and therapy. The pattern was massive: 1,025 sufferers {followed} up for a median of 4 years, or 3,366 person-years in complete. Blood outcomes got here from laboratory exams recorded by a UK clozapine monitoring service, the Zaponex Therapy Entry System, which reduces the chance of measurement bias. The pattern was additionally ethnically various (48% White, 30% Black, 11% Asian, 3% combined and eight% different) and included individuals with benign ethnic neutropenia. The paper doesn’t say who was within the “different” group.

There are additionally necessary limitations.

First, there was no management group of sufferers on customary 4-weekly monitoring. This implies the examine can present that the chance was low on 12-weekly monitoring, however not that 12-weekly monitoring is as secure as 4-weekly.
Second, the pattern was extremely chosen. Sufferers needed to have taken clozapine reliably for at the least a 12 months with no historical past of neutropenia, and on common they’d been taking it for 10 years. The chance of agranulocytosis is highest early in therapy and really low after that. So this was a low-risk group, and the findings might not apply to everybody presently on 4-weekly monitoring.
Third, agranulocytosis is uncommon, so even a big examine can miss it. The authors cite an anticipated price after the primary 12 months of 0.31 to 0.52 circumstances per 1,000 person-years (Schulte, 2006). With no circumstances in 3,366 person-years, the true price might nonetheless be as excessive as about 0.9 per 1,000 person-years (the higher 95% confidence restrict). So the examine can not rule out a price at or above the standard background threat.
Fourth, key particulars weren’t reported. The examine didn’t report clozapine dose, smoking standing (which impacts clozapine ranges), different medicines or previous medical historical past. Different medicines matter as a result of some, corresponding to carbimazole, co-trimoxazole, carbamazepine and azathioprine, may also trigger agranulocytosis. We additionally don’t know what occurred to the 9 sufferers with a pink end result, why 9 deaths had an unknown trigger, or something concerning the one dying recorded as clozapine associated.
Lastly, the info got here from solely one of many three UK clozapine monitoring companies. The outcomes might not mirror sufferers registered with the opposite two.

An abstract image of people — Inclusion standards might have led to a pattern of decrease threat sufferers being chosen.

Implications for apply

After the primary 12 months of therapy, UK product licences presently require blood exams at the least each 4 weeks, so long as neutrophil counts are secure (Viatris, 2026; Leyden Delta BV, 2024). Agranulocytosis will not be the one motive to cease clozapine. Different probably critical blood circumstances, corresponding to eosinophilia (a excessive degree of eosinophils, a sort of white blood cell) and thrombocytopenia (low platelets), additionally present up within the full blood rely. Any change to monitoring must preserve these in view.

Clozapine works for individuals with treatment-resistant schizophrenia. It reduces hospital readmissions and lowers suicide threat (Fernandez-Egea et al., 2024), but it stays underused. Frequent blood exams are one motive: they’re a burden, and so they can lead individuals to cease therapy or disengage from care.

This examine provides to the proof that 12-weekly monitoring could also be affordable for some individuals who have taken clozapine for a very long time and have secure blood counts. There have been no circumstances of agranulocytosis and no deaths from it. However it is a single observational examine with no management group and a low-risk pattern, so by itself it isn’t sufficient to vary apply for everybody.

The deaths on this examine additionally level to a special threat. Respiratory illness was the commonest reason for dying, and no deaths had been because of agranulocytosis. Because the authors be aware, pneumonia might matter extra for clozapine security than agranulocytosis. Measures such because the pneumococcal vaccine, and fast therapy of chest infections, deserve as a lot consideration because the blood check schedule.

Blood exams are sometimes an everyday level of contact with companies. For individuals who reside alone or have little assist, fewer exams might imply fewer probabilities to identify issues early or to ask for assist. However, frequent exams can really feel like a burden and should push some individuals away from care. If blood exams develop into much less frequent, different contact with the care workforce ought to keep it up, in order that fewer exams don’t imply much less assist.

With fewer blood exams, individuals will rely extra on recognizing and reporting the indicators of agranulocytosis themselves. These embody fever, chills, flu-like signs, a sore throat or mouth sores, excessive tiredness, and weak spot brought on by a drop in blood strain. Clear info and good conversations about clozapine and its unwanted effects are important. This can be tougher for older adults and for individuals with cognitive impairment or impaired decision-making capability, who might discover it tough to recognise or talk new signs. They could want further assist from household, carers or workers.

Extra analysis is required earlier than tips change. Research that evaluate 12-weekly with 4-weekly monitoring, and systematic critiques that carry the rising proof collectively, would assist. Any change to apply would additionally want settlement from the clozapine monitoring companies and modifications to the product licences.